1. Usulan rekomendasi
Diusulkan untuk direkomendasikan
Tikagrelor diusulkan untuk direkomendasikan untuk sindrom koroner akut.
Alasan usulan
- Dibandingkan dengan klopidogrel ditambah aspirin, tikagrelor memberi tambahan 0,20 tahun hidup berkualitas (QALY) per pasien dengan tambahan biaya Rp 8,3 juta per pasien.
- Rasio biaya terhadap manfaat sebesar Rp 42,3 juta per QALY berada di bawah acuan satu kali PDB per kapita (Rp 75 juta per QALY).
2. Informasi tentang tikagrelor
| Nama generik | Tikagrelor (ticagrelor) |
|---|---|
| Kode ATC | B01AC24 |
| Bidang terapi | Darah dan organ pembentuk darah |
| Program penilaian | Penilaian obat baru |
| Intervensi yang dinilai | Tikagrelor ditambah aspirin |
| Pembanding | klopidogrel ditambah aspirin |
| Formularium Nasional | Tercantum (FKRTL) |
| Izin edar BPOM | Ya |
| Katalog elektronik pengadaan | Ya |
| Daftar Obat Esensial WHO | Ya |
| Perluasan akses FKTP | Reasesmen 3: Hanya dijamin di FKRTL dan tercantum dalam Daftar Obat Esensial WHO, atau sudah memiliki penilaian teknologi kesehatan. |
| Biaya obat dalam model (per tahun atau per rangkaian terapi) | Rp 6 juta |
3. Pembahasan bukti
| Ukuran | Nilai |
|---|---|
| Tambahan tahun hidup berkualitas per pasien | 0,197 QALY |
| Tambahan biaya per pasien | Rp 8,3 juta |
| Rasio biaya terhadap manfaat | Rp 42,3 juta per QALY |
| Peluang hemat biaya pada Rp 75 juta per QALY | 84,4% |
Hasil lengkap, termasuk simulasi probabilistik dan analisis sensitivitas, tersedia pada halaman bukti.
Keterbatasan
Uraian berikut tersedia dalam bahasa Inggris.
- Drug-acquisition costs are the authoritative Indonesian e-Katalog LKPP (BPJS procurement) net prices (ticagrelor 90 mg Rp 8,325/tab; clopidogrel 75 mg Rp 715/tab); these resolve the single most influential divergence between the two independent builders, who had both used unverified retail/generic proxies. e-Katalog tender prices can change between procurement cycles and should be re-confirmed.
- Treatment effect is confined to the 12-month DAPT window per the NICE TA236 economic model (paragraph 3.11: the beneficial effect of ticagrelor does not persist beyond 1 year); both independent builder arms had instead let the PLATO hazard ratios persist across the full modelled horizon, which materially overstated incremental QALYs. The adjudicated model corrects this by applying the HRs to year-1 transitions only and using identical year>=2 transition probabilities for both arms.
- PLATO efficacy hazard ratios are from a global RCT; East Asian / Indonesian patients may differ in ischaemic and bleeding risk, and some East Asian data suggest higher bleeding with potent P2Y12 inhibitors. The stroke HR (1.17) and major-bleeding HR (1.04) were not statistically significant in PLATO but are retained at their point estimates for fidelity and tested in PSA.
- PLATO data integrity was questioned in a 2024 BMJ investigation; the published HRs are used here as the regulatory/NICE-accepted base case, with this caveat flagged for expert review.
- Indonesia-specific post-ACS transition probabilities, EQ-5D health-state utilities, and INA-CBG cardiovascular tariff codes were not directly available; values are calibrated to PLATO, NICE TA236, UK fallback utilities, and Indonesian ACS registry mortality, requiring local validation (SKI, JKN claims, SMART-REACH inpatient cost data).
- The model represents ticagrelor bleeding/dyspnoea harms as a per-cycle disutility, a small added care cost, and an explicit post_major_bleed state, rather than as fully time-resolved transient bleeding events; twice-daily adherence below trial levels would attenuate real-world benefit and is not modelled in the base case.
- Chronic (year >=2) post-ACS background event and mortality rates are extrapolations from secondary-prevention literature and the NICE TA236 Markov assumptions, not an Indonesia-specific longitudinal ACS cohort.
4. Implementasi
Dengan perkiraan 250.000 pasien yang memenuhi syarat, dampak anggaran kumulatif lima tahun diperkirakan tambahan belanja Rp 1,8 triliun. Rincian per tahun tersedia pada halaman implementasi.
Penilaian kapasitas layanan, kesiapan implementasi, dan kesetaraan belum tersedia untuk topik ini.
5. Tim penilai dan status telaah
| Status telaah | Draf, menunggu telaah ahli ekonomi kesehatan |
|---|---|
| Penyusun analisis | ARC Institute |
| Pengesahan komite | Belum ada |